Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01996644 · ClinicalTrials.gov registry record · NA
A Double Blind Clinical Trial of DCS for Food Anxiety
A NA study of Anorexia and Bulimia Nervosa, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT01996644: Completed NA study of Anorexia and Bulimia Nervosa, sponsored by Washington University School of Medicine.
NCT01996644 is a NA study of Anorexia and Bulimia Nervosa that has completed, run by Washington University School of Medicine. The registered enrollment target is 47 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01996644, a NA study of Anorexia and Bulimia Nervosa, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study investigating if cycloserine (DCS; a learning enhancement medication) augments exposure therapy for food anxiety in patients with anorexia and bulimia nervosa. The investigators expect that (a) exposure therapy will reduce anxiety (b) anxiety will be reduced more in the DCS relative to placebo condition (c) participants in the DCS condition will have a greater increase in Body Mass Index.
Primary Outcome
Anxiety will be measured at 4 sessions, twice a week for two weeks. Anxiety is combined in a repeated measures ANOVA to give total anxiety decreased across condition. Anxiety was measured using the Subjective Units of Distress (ranging from 1 to 100), where 1 is no anxiety and 100 is the most anxiety ever experienced.
Conditions Studied
Interventions
- DRUG Placebo vs Setraline
- DRUG Setraline
Study Locations (1)
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-02 |
| Phase | NA |
What the finished NCT01996644 record still lists
NCT01996644 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Anorexia and Bulimia Nervosa appearing as the primary indexed condition, and to 2 interventions - of which Placebo vs Setraline is the first listed.
NCT01996644 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT01996644 about?
NCT01996644 is a clinical study titled "A Double Blind Clinical Trial of DCS for Food Anxiety". This is a pilot study investigating if cycloserine (DCS; a learning enhancement medication) augments exposure therapy for food anxiety in patients with anorexia and bulimia nervosa. The investigators expect that (a) exposure therapy will reduce anxiety (b) anxiety will be reduced more in the DCS rel...
What is the current status of trial NCT01996644?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2013-02. Estimated completion is 2014-02.
What conditions does trial NCT01996644 study?
This clinical trial studies the following conditions: Anorexia and Bulimia Nervosa.
What interventions are being tested in trial NCT01996644?
The interventions under investigation include: Placebo vs Setraline (DRUG), Setraline (DRUG).
Who is sponsoring clinical trial NCT01996644?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01996644 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01996644's enrollment target sits among peer trials
47 1400th of 2000 higher than 599 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia